Shin Nippon Biomedical Laboratories, Ltd. (2395.T)
JPY 1537.0
(-1.22%)
JPY 1537.0
(-1.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.16 Billion JPY | -20.64% |
| 2022 | 5.24 Billion JPY | 25.02% |
| 2021 | 4.19 Billion JPY | 65.86% |
| 2020 | 2.52 Billion JPY | 13.52% |
| 2019 | 2.22 Billion JPY | 168.53% |
| 2018 | 829.79 Million JPY | 218.97% |
| 2017 | -697.47 Million JPY | 61.09% |
| 2016 | -1.79 Billion JPY | 53.6% |
| 2015 | -3.86 Billion JPY | -507.17% |
| 2014 | -636.3 Million JPY | 12.09% |
| 2013 | -723.76 Million JPY | 49.32% |
| 2012 | -1.42 Billion JPY | 53.16% |
| 2011 | -3.04 Billion JPY | -261.39% |
| 2010 | -843.65 Million JPY | -345.37% |
| 2009 | 343.83 Million JPY | -25.89% |
| 2008 | 463.93 Million JPY | -70.74% |
| 2007 | 1.58 Billion JPY | 40.85% |
| 2006 | 1.12 Billion JPY | 45.79% |
| 2005 | 772.2 Million JPY | 334.73% |
| 2004 | -328.96 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -145.18 Million JPY | -108.93% |
| 2023 Q1 | 1.22 Billion JPY | -16.03% |
| 2023 Q2 | 1.12 Billion JPY | -8.53% |
| 2023 Q3 | 186.25 Million JPY | -83.41% |
| 2023 Q4 | 1.62 Billion JPY | 773.35% |
| 2023 FY | 4.16 Billion JPY | -20.64% |
| 2022 Q1 | 714.01 Million JPY | -20.23% |
| 2022 Q3 | 1.47 Billion JPY | -8.1% |
| 2022 Q4 | 1.46 Billion JPY | -0.6% |
| 2022 FY | 5.24 Billion JPY | 25.02% |
| 2022 Q2 | 1.59 Billion JPY | 124.05% |
| 2021 Q2 | 1.47 Billion JPY | 200.43% |
| 2021 FY | 4.19 Billion JPY | 65.86% |
| 2021 Q1 | 491.82 Million JPY | -45.56% |
| 2021 Q3 | 1.33 Billion JPY | -9.91% |
| 2021 Q4 | 895.1 Million JPY | -32.75% |
| 2020 Q1 | 447.7 Million JPY | -31.25% |
| 2020 FY | 2.52 Billion JPY | 13.52% |
| 2020 Q4 | 903.48 Million JPY | 94.46% |
| 2020 Q2 | 713.72 Million JPY | 59.42% |
| 2020 Q3 | 464.61 Million JPY | -34.9% |
| 2019 Q1 | 273.46 Million JPY | -43.95% |
| 2019 Q2 | 805.12 Million JPY | 194.42% |
| 2019 Q3 | 498.43 Million JPY | -38.09% |
| 2019 FY | 2.22 Billion JPY | 168.53% |
| 2019 Q4 | 651.23 Million JPY | 30.66% |
| 2018 Q2 | 4.65 Million JPY | 103.28% |
| 2018 Q3 | 479.19 Million JPY | 10189.67% |
| 2018 Q4 | 487.85 Million JPY | 1.81% |
| 2018 FY | 829.79 Million JPY | 218.97% |
| 2018 Q1 | -141.9 Million JPY | -129.16% |
| 2017 Q4 | 486.71 Million JPY | 220.23% |
| 2017 Q3 | -404.8 Million JPY | -398.19% |
| 2017 Q2 | -81.25 Million JPY | 88.36% |
| 2017 FY | -697.47 Million JPY | 61.09% |
| 2017 Q1 | -698.12 Million JPY | -329.9% |
| 2016 FY | -1.79 Billion JPY | 53.6% |
| 2016 Q2 | -766.49 Million JPY | 19.07% |
| 2016 Q3 | -382.54 Million JPY | 50.09% |
| 2016 Q4 | 303.66 Million JPY | 179.38% |
| 2016 Q1 | -947.12 Million JPY | -60.13% |
| 2015 Q3 | -884.83 Million JPY | 14.53% |
| 2015 Q2 | -1.03 Billion JPY | 23.43% |
| 2015 Q1 | -1.35 Billion JPY | -569.94% |
| 2015 FY | -3.86 Billion JPY | -507.17% |
| 2015 Q4 | -591.46 Million JPY | 33.16% |
| 2014 Q4 | 287.68 Million JPY | 626.11% |
| 2014 FY | -636.3 Million JPY | 12.09% |
| 2014 Q3 | -54.68 Million JPY | 84.96% |
| 2014 Q2 | -363.63 Million JPY | 28.09% |
| 2014 Q1 | -505.66 Million JPY | -184.99% |
| 2013 Q2 | -485.44 Million JPY | 5.59% |
| 2013 Q1 | -514.18 Million JPY | 2.8% |
| 2013 Q3 | -319.11 Million JPY | 34.26% |
| 2013 FY | -723.76 Million JPY | 49.32% |
| 2013 Q4 | 594.96 Million JPY | 286.44% |
| 2012 Q2 | -369.58 Million JPY | -44.96% |
| 2012 Q3 | -274.56 Million JPY | 25.71% |
| 2012 FY | -1.42 Billion JPY | 53.16% |
| 2012 Q1 | -254.95 Million JPY | 83.39% |
| 2012 Q4 | -528.97 Million JPY | -92.66% |
| 2011 FY | -3.04 Billion JPY | -261.39% |
| 2011 Q4 | -1.53 Billion JPY | -263.8% |
| 2011 Q3 | -422 Million JPY | 36.13% |
| 2011 Q2 | -660.76 Million JPY | -53.35% |
| 2011 Q1 | -430.9 Million JPY | -541.88% |
| 2010 Q4 | -67.13 Million JPY | 23.01% |
| 2010 Q3 | -87.19 Million JPY | 65.68% |
| 2010 Q1 | -435.29 Million JPY | -280.6% |
| 2010 FY | -843.65 Million JPY | -345.37% |
| 2010 Q2 | -254.03 Million JPY | 41.64% |
| 2009 Q3 | -121.58 Million JPY | -158.09% |
| 2009 Q4 | -114.37 Million JPY | 5.93% |
| 2009 FY | 343.83 Million JPY | -25.89% |
| 2009 Q1 | 370.48 Million JPY | 170.31% |
| 2009 Q2 | 209.3 Million JPY | -43.51% |
| 2008 Q3 | -229.92 Million JPY | -817.63% |
| 2008 FY | 463.93 Million JPY | -70.74% |
| 2008 Q4 | 137.06 Million JPY | 159.61% |
| 2008 Q2 | 32.03 Million JPY | 0.0% |
| 2007 FY | 1.58 Billion JPY | 40.85% |
| 2006 FY | 1.12 Billion JPY | 45.79% |
| 2005 FY | 772.2 Million JPY | 334.73% |
| 2004 FY | -328.96 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| DNA Chip Research Inc. | -258.21 Million JPY | 1711.968% |
| Cosmo Bio Company,Limited | 519 Million JPY | -701.996% |
| H.U. Group Holdings, Inc. | -4.04 Billion JPY | 202.952% |
| FALCO HOLDINGS Co., Ltd. | 2.15 Billion JPY | -93.418% |
| BML, Inc. | 9.16 Billion JPY | 54.599% |
| Human Metabolome Technologies, Inc. | 220.16 Million JPY | -1790.538% |
| Precision System Science Co., Ltd. | -956.24 Million JPY | 535.281% |